Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Net Income | 16.61% | 26.32% | -31.56% | 70.98% | -21.88% |
| Total Depreciation and Amortization | 2.38% | -25.00% | 0.00% | -22.22% | 425.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.26% | 727.78% | 666.48% | -92.99% | 105.96% |
| Change in Net Operating Assets | 128.37% | 888.24% | 65.30% | -704.08% | 32.68% |
| Cash from Operations | 46.33% | 52.02% | 19.45% | -123.16% | 6.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -68.50% | 359.70% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -67.11% | -112.02% | 118.65% | -68.11% | 383.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.83% | -238.32% | 289.65% | -373.53% | 153.77% |
